Vertex to acquire US biotech firm Semma Therapeutics for £785m

This article was originally published here

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type

The post Vertex to acquire US biotech firm Semma Therapeutics for £785m appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply